A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904).
Publication
, Conference
Kulke, MH; Niedzwiecki, D; Tempero, MA; Hollis, DR; Mayer, RJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
316S / 316S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kulke, M. H., Niedzwiecki, D., Tempero, M. A., Hollis, D. R., & Mayer, R. J. (2004). A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 316S-316S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
Kulke, M. H., D. Niedzwiecki, M. A. Tempero, D. R. Hollis, and R. J. Mayer. “A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904).” In JOURNAL OF CLINICAL ONCOLOGY, 22:316S-316S. AMER SOC CLINICAL ONCOLOGY, 2004.
Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 316S-316S.
Kulke, M. H., et al. “A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904).” JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 14, AMER SOC CLINICAL ONCOLOGY, 2004, pp. 316S-316S.
Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 316S-316S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
316S / 316S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences